The study aimed to evaluate the efficacy and safety of drug coated balloon-only strategy (DCB-only) in the treatment of de novo left main coronary artery (LM) bifurcation lesions. 85 patients were enrolled in this study and classified them into two groups: DCB-only group (n = 36) and DES group (n = 49). The MLD of target vessels was measured before and immediately after percutaneous coronary intervention (PCI) and late luminal loss (LLL) were also calculated. And the occurrence of major adverse cardiovascular events (MACE) was also evaluated. Compared with that before PCI, the MLD of target lesions significantly increased immediately after PCI (P < .05) and no MACE was recorded during the perioperative period both in two groups. The MLD at follow-up was significantly higher than that before both DCB and DES treatment. Compared with the DES group, the MLD of the DCB group was smaller than immediately after PCI in the LM and LAD (P < .05). The LLL of LAD in DCB group was smaller than that in DES group (P < .05). There was no significant difference in the incidence of luminal restenosis at the target lesion between the two groups, and no significant difference in the incidence of MACE (P > .05). The use of DCB-only to treat de novo LM bifurcation lesions is effective and relatively safe, which provides new ideas for the treatment of LM coronary artery bifurcation lesions in the future.

该研究旨在评估仅药物涂层球囊策略（仅 DCB）在治疗从头左冠状动脉主干 (LM) 分叉病变中的疗效和安全性。85 名患者参加了这项研究，并将他们分为两组：仅 DCB 组（n = 36）和 DES 组（n = 49）。在经皮冠状动脉介入治疗（PCI）之前和之后立即测量靶血管的MLD，并计算晚期管腔丢失（LLL）。并且还评估了主要不良心血管事件（MACE）的发生。与PCI前相比，PCI术后即刻靶病灶MLD显着升高（P < .05) 且两组在围手术期均未记录到 MACE。随访时的 MLD 均显着高于 DCB 和 DES 治疗前。与 DES 组相比，DCB 组 LM 和 LAD 的 MLD 小于 PCI 后即刻（P  < .05）。DCB组LAD LLL小于DES组( P  < .05)。两组靶病灶管腔再狭窄发生率差异无统计学意义，MACE发生率差异无统计学意义（P  >.05）。仅使用DCB治疗从头LM分叉病变有效且相对安全，为今后LM冠状动脉分叉病变的治疗提供了新思路。